Revenue of $2.2 million and backlog1 of $23.0
million
Rockley Photonics Holdings Limited (NYSE: RKLY) (“the Company”
or “Rockley”), a leading global silicon photonics technology
company, today announced its financial results for the second
quarter ended June 30, 2021.
The second quarter results for Rockley reflect the results for
the three months ended June 30, 2021, for Rockley Photonics
Limited, prior to the closing on August 11, 2021, of the recent
business combination among Rockley’s predecessor, Rockley Photonics
Limited, SC Health Corporation, a public investment vehicle, and
the Company, pursuant to which Rockley Photonics Limited became a
wholly owned subsidiary of the Company.2
“I am pleased to announce our first financial
results as a publicly-traded company. I believe that as a public
company, we are in a stronger position than ever before to develop
new solutions with potentially life-changing benefits to people
across the globe,” said Dr. Andrew Rickman, chief executive officer
and founder of Rockley Photonics. “We’re excited about the advances
we’ve made over the past few years and, more recently, in the
development of our new sensing platform. By designing the ability
to measure a new range of biomarkers non-invasively into a single,
compact module, we believe our mobile sensing solution has the
potential to transform the landscape of health and wellness
solutions by significantly increasing the functionality of wearable
devices. Our success in the development of photonic solutions like
this, along with our entrance into the public markets, has
attracted world-renowned customers and partners who understand the
unique opportunities that Rockley presents.”
In recent months, Rockley achieved several key milestones.
During second quarter, the Company announced its new end-to-end
platform for monitoring biomarkers non-invasively. Additionally,
through existing agreements and joint ventures, Rockley has
continued to develop commercial opportunities for the application
of silicon photonics in data communications and has increased its
efforts to enhance these relationships and explore new
partnerships.
1 Backlog is signed contract revenue that is currently in
progress or the portion of contracts that have not been
invoiced.
2 References in this press release to the Company and Rockley
may also refer to Rockley Photonics Limited or the combined company
as the context requires.
Additional Business Highlights:
- Completed business combination with SC Health on August 11,
2021, and commenced trading on the NYSE under the ticker “RKLY,”
advancing the Company’s development of exciting new health and
wellness solutions for the next generation of consumer wearables
and medical devices;
- Increased cash position to $145.5 million which will fund the
continued development of our portfolio of integrated photonics
solutions following the Company's business combination with SC
Health;
- Unveiled end-to-end digital health monitoring solution based on
spectrophotometer-on-a-chip sensing module to augment the Company’s
wearables capabilities and to accelerate the deployment for
customers and partners;
- Bolstered its operational capability for future growth with the
continued development of a resilient and scalable supply chain;
and
- Completed the construction of its Irvine, CA laboratory to
capitalize on the deep silicon photonics and biomedical talent pool
located in the area.
Pre-Business Combination Second Quarter 2021 Financial
Highlights:
- Revenue of $2.2 million, compared to $1.8 million in the first
quarter of 2021;
- Gross profit of $(2.4) million, compared to $(2.0) million in
the first quarter of 2021;
- GAAP selling, general, and administrative expenses of $6.7
million, compared to $7.3 million in the first quarter of 2021.
Non-GAAP selling, general, and administrative expenses of $6.2
million, compared to $5.9 million in the first quarter of
2021;
- GAAP research and development expenses of $17.6 million,
compared to $16.0 million in the first quarter of 2021. Non-GAAP
research and development expenses of $16.4 million, compared to
$14.9 million in the first quarter of 2021;
- Net loss of $30.6 million, compared to a $64.8 million net loss
in the first quarter of 2021;
- Adjusted EBITDA totaled $(23.4) million, compared to $(21.4)
million in the first quarter of 2021;
- Cash position, with cash and cash equivalents of $35.4 million
as of June 30, 2021; and
- Cash used in operations of $29.6 million, compared to $24.9
million in the first quarter of 2021.
A reconciliation of GAAP financial measures to Adjusted EBITDA
(Non-GAAP) financial measures is included in the financial
statement tables included in this press release.
Conference Call Information
Rockley Photonics will host a conference call and webcast to
discuss its second quarter 2021 results at 5:00 p.m. Eastern Time
today. The live audio webcast along with accompanying presentation
materials will be accessible on the Company’s Investor Relations
website at investors.rockleyphotonics.com.
The U.S. dial-in for the call is 844-200-6205 or +44
208-0682-558 for international callers. Please reference access
code 821259. A replay of the conference call will be available
until August 30, 2021, at 11:59 p.m. Eastern Time, while an
archived version of the webcast will be available on Rockley’s
Investor Relations website for one year. The U.S. dial-in for the
conference call replay is +1 929-458-6194 or +44 204-525-0658. The
replay access code is 348691.
About Rockley Photonics
A global leader in silicon photonics, Rockley is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013 by Dr. Andrew Rickman (who previously founded the
first commercial silicon photonics company, Bookham Technology),
Rockley is uniquely positioned to support hyper-scale manufacturing
and address a multitude of high-volume markets. Rockley has
partnered with numerous Tier-1 customers across a diverse range of
industries to deliver the complex optical systems required to bring
transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements in this press release that are not historical
facts constitute “forward-looking statements” for purposes of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “anticipate,” “believe,” “continue,” “could,” “enable,”
“estimate,” “eventual,” “expect,” “future,” “intend,” “may,”
“might,” “opportunity,” “outlook,” “plan,” “possible,” “position,”
“potential,” “predict,” “project,” “revolutionize,” “seem,”
“should,” “trend,” “will,” “would” and other terms that predict or
indicate future events, trends, or expectations, and similar
expressions or the negative of such expressions may identify
forward-looking statements, but the absence of these words or terms
does not mean that a statement is not forward-looking.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the following: (a) the
Company’s position to develop new solutions with potentially
life-changing benefits; (b) the potential of the Company’s mobile
sensing solution to transform the landscape of health and wellness
solutions; (c) the unique opportunities that Rockley presents; (d)
the Company’s continued development of commercial opportunities for
the application of silicon photonics and its efforts to enhance
existing and explore new partnerships; (e) the Company’s plans and
anticipated use of cash to fund the continued development of its
portfolio of integrated photonics solutions; (f) the potential to
accelerate the deployment of the Company’s digital health
monitoring solution for customers and partners; (g) the Company’s
ability to bolster its operational capability for future growth
with the continued development of a resilient and scalable supply
chain; and (h) the anticipated and potential features and benefits
of the Company’s platform, products, and technology.
Forward-looking statements are subject to several risks and
uncertainties (many of which are beyond the Company’s control) or
other assumptions that may cause actual results or performance to
differ materially from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the following: (i) the Company’s ability to
achieve commercial production of its products and technology,
including in a timely and cost-effective manner; (ii) the Company’s
ability to achieve customer design wins, convert memoranda of
understanding and development contracts into production contracts,
and achieve customer acceptance of its products and technology;
(iii) risks related to purchase orders, including the lack of
long-term purchase commitments, the cancellation, reduction, delay,
or other changes in customer purchase orders, and if and to the
extent customers seek to enter into licensing arrangements in lieu
of purchases; (iv) the Company’s history of losses and need for
additional capital and its ability to access additional financing
to support its operations and execute on its business plan, as well
as the risks associated with any future financings; (v) legal and
regulatory risks, including those related to its products and
technology and any threatened or actual litigation; (vi) risks
associated with its fabless manufacturing model and dependency on
third-party suppliers; (vii) the Company’s reliance on a few
significant customers for a majority of its revenue and its ability
to expand and diversify its customer base; (viii) the Company’s
financial performance; (ix) the impacts of COVID-19 on the Company,
its customers and suppliers, its target markets, and the economy;
(x) the Company’s ability to successfully manage growth and its
operations as a public company; (xi) fluctuations in the Company’s
stock price and the Company’s ability to maintain the listing of
its ordinary shares on the NYSE; (xii) the Company’s ability to
anticipate and respond to industry trends and customer
requirements; (xiii) changes in the Company’s current and future
target markets; (xiv) intellectual property risks; (xv) the
Company’s ability to compete successfully; (xvi) market opportunity
and market demand for, and acceptance of, the Company’s products
and technology, as well as the customer products into which the
Company’s products and technology are incorporated; (xvii) risks
related to international operations; (xviii) risks related to
cybersecurity, privacy, and infrastructure; (xix) risks related to
financial and accounting matters; (xx) general economic, financial,
legal, political, and business conditions and changes in domestic
and foreign markets; (xxi) the Company’s ability to realize the
anticipated benefits of the business combination; and (xxii)
changes adversely affecting the businesses or markets in which the
Company is engaged, as well as other factors described under the
heading “Risk Factors” in the prospectus/proxy statement filed by
the Company on July 22, 2021, the Company’s quarterly report on
Form 10-Q for the quarter ended June 30, 2021, and in other
documents the Company files with the Securities and Exchange
Commission in the future. The forward-looking statements contained
in this press release are based on various assumptions, whether or
not identified in this press release, and on the Company’s current
expectations, beliefs, and assumptions and are not predictions of
actual performance. If any of these risks or uncertainties
materialize, or should any of these assumptions prove incorrect,
actual results may differ materially from those discussed in or
implied by these forward-looking statements. There can be no
assurance that future developments affecting the Company will be
those that have been anticipated. These forward-looking statements
speak only as of the date hereof and the Company specifically
disclaims any obligation to update or revise any forward-looking
statements, whether because of new information, future events, or
otherwise.
Second Quarter 2021 Financial Results
ROCKLEY PHOTONICS HOLDINGS
LIMITED
Condensed Consolidated
Statements of Operations and Comprehensive Loss
(Unaudited and in thousands,
except share and per share amounts)
Three Months Ended
Six Months Ended
June 30, 2021
March 31, 2021
June 30, 2020
June 30, 2021
June 30, 2020
Revenue
$
2,195
$
1,771
$
7,881
$
3,966
$
14,544
Cost of revenue
4,549
3,734
6,522
8,283
13,085
Gross profit
(2,354
)
(1,963
)
1,359
(4,317
)
1,459
Operating expenses:
Selling, general and administrative
expenses
6,715
7,305
3,604
14,020
7,249
Research and development expenses
17,551
15,980
7,746
33,531
16,217
Total operating expenses
24,266
23,285
11,350
47,551
23,466
Loss from operations
(26,620
)
(25,248
)
(9,991
)
(51,868
)
(22,007
)
Other income (expense):
Forgiveness of PPP loan
2,860
—
—
2,860
—
Interest expense, net
(179
)
(147
)
(34
)
(326
)
(74
)
Equity method investment loss
(597
)
(163
)
(102
)
(760
)
(252
)
Change in fair value of debt
instruments
(6,008
)
(39,653
)
312
(45,661
)
(2,222
)
Gain (loss) on foreign currency
97
534
(108
)
631
(1,654
)
Total other income (expense)
(3,827
)
(39,429
)
68
(43,256
)
(4,202
)
Loss before income taxes
(30,447
)
(64,677
)
(9,923
)
(95,124
)
(26,209
)
Provision for income tax
110
100
80
210
220
Net loss and comprehensive loss
$
(30,557
)
$
(64,777
)
$
(10,003
)
$
(95,334
)
$
(26,429
)
Net loss per share:
Basic and diluted
$
(0.90
)
$
(1.92
)
$
(0.30
)
$
(2.82
)
$
(0.79
)
Weighted-average shares
outstanding:
Basic and diluted
33,922,973
33,776,356
33,625,899
33,850,070
33,554,441
ROCKLEY PHOTONICS HOLDINGS
LIMITED
Condensed Consolidated Balance
Sheets
(in thousands, except share
amounts and par value)
As of
June 30, 2021
December 31,
2020
(Unaudited)
Assets
Current assets
Cash and cash equivalents
$
35,395
$
19,228
Accounts receivable, net of allowance for
doubtful accounts of $377 and $0 as of June 30, 2021 and December
31, 2020, respectively
2,411
4,925
Other receivables
23,037
18,024
Prepaid expenses
7,724
1,605
Other current assets
258
609
Total current assets
68,825
44,391
Property, equipment, and finance lease
right-of-use assets, net
8,170
6,182
Equity method investment
4,711
5,202
Intangible assets, net
3,048
3,048
Other non-current assets
11,715
1,607
Total assets
$
96,469
$
60,430
Liabilities and Stockholders’
Deficit
Current liabilities
Trade payables
$
8,692
$
4,413
Accrued expenses
12,104
10,395
Other current liabilities
1,020
998
Total current liabilities
21,816
15,806
Long-term debt
194,328
74,804
Other long-term liabilities
2,719
1,127
Total liabilities
218,863
91,737
Stockholders’ deficit
Ordinary shares, $0.00001 par value;
55,982,833 authorized as of June 30, 2021 and December 31, 2020;
33,825,620 and 33,637,762 issued and outstanding as of June 30,
2021 and December 31, 2020, respectively
—
—
Additional paid-in-capital
205,823
201,576
Accumulated deficit
(328,217
)
(232,883
)
Total stockholders’ deficit
(122,394
)
(31,307
)
Total liabilities and stockholders’
deficit
$
96,469
$
60,430
ROCKLEY PHOTONICS HOLDINGS
LIMITED
Condensed Consolidated
Statements of Cash Flows
(Unaudited and in thousands)
Three Months Ended
Six Months Ended
June 30, 2021
March 31, 2021
June 30, 2020
June 30, 2021
June 30, 2020
Cash flows from operating
activities:
Net loss
$
(30,557
)
$
(64,777
)
$
(10,003
)
$
(95,334
)
$
(26,429
)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization of property,
equipment and finance lease right-of-use assets
1,069
930
706
1,999
1,395
Gain on disposal of property and
equipment
—
(98
)
Bad debt expense
—
377
—
377
—
Stock-based compensation
1,976
1,725
2,545
3,701
4,189
Change in equity-method investment
604
(113
)
102
491
252
Change in fair value of debt
instrument
6,008
39,653
(312
)
45,661
2,222
Forgiveness of Paycheck Protection Program
loan
(2,860
)
—
—
(2,860
)
—
Changes in operating assets and
liabilities:
—
—
Accounts receivable
(106
)
2,243
(921
)
2,137
(1,382
)
Other receivables
(2,644
)
(2,369
)
10,588
(5,013
)
8,602
Prepaid expenses and other current
assets
(63
)
(5,706
)
697
(5,769
)
1,263
Other non-current assets
(236
)
(1,497
)
180
(1,733
)
357
Trade payables
(2,102
)
1,972
(709
)
(130
)
(4,347
)
Accrued expenses
(441
)
843
(1,432
)
402
1,708
Other current and long-term
liabilities
(206
)
1,820
(38
)
1,614
(838
)
Net cash used in operating activities
(29,558
)
(24,899
)
1,403
(54,457
)
(13,106
)
Cash flows from investing
activities:
Purchase of property and equipment
(2,109
)
(437
)
(713
)
(2,822
)
(650
)
Payment for asset acquisition
(500
)
—
—
(500
)
—
Investment in equity method investee
—
(2,500
)
—
—
(2,500
)
Net cash used in investing activities
(2,609
)
(2,937
)
(713
)
(3,322
)
(3,150
)
Cash flows from financing
activities:
Proceeds from convertible loan notes
—
76,723
3,900
76,723
12,250
Principal payments on long-term debt
—
—
(1,033
)
—
(1,952
)
Proceeds from issuance of ordinary shares,
net of issuance costs
—
—
(2,213
)
—
(126
)
Proceeds from Paycheck Protection Program
loan
—
—
—
—
2,860
Proceeds from exercise of options
146
137
2,094
283
2,114
Proceeds for warrants to be exercised
—
263
—
233
—
Proceeds from issuance of warrants
233
—
(7
)
263
—
Debt issuance costs incurred
(2,416
)
(1,140
)
649
(3,556
)
—
Principal payments on finance lease
—
—
(1,231
)
—
(1,231
)
Net cash provided by financing
activities
(2,037
)
75,983
2,159
73,946
13,915
Net increase (decrease) in cash and
cash equivalents
(34,204
)
48,147
2,849
16,167
(2,341
)
Cash and cash equivalents:
Beginning of period
69,599
19,228
15,176
19,228
20,904
End of period
$
35,395
$
69,599
$
18,563
$
35,395
$
18,563
Use of Non-GAAP Financial Measures
This press release references certain financial measures that
are not prepared in accordance with generally accepted accounting
principles in the United States (GAAP), including Adjusted EBITDA,
non-GAAP cost of revenue, non-GAAP selling, general, and
administrative expense and non-GAAP research and development
expense. The Company defines Adjusted EBITDA as earnings before
interest expense, taxes, depreciation and amortization, stock-based
compensation, and certain other items the Company believes are not
indicative of its core operating performance. The Company defines
non-GAAP cost of revenue as cost of revenue as cost of revenue
other than stock-based compensation, non-GAAP selling, general, and
administrative expenses as selling, general, and administrative
expenses other than stock-based compensation, non-capitalized
transaction costs and forgiveness of PPP loan, and non-GAAP
research and development expenses as research and development
expenses other than stock-based compensation. None of these
non-GAAP financial measures is a substitute for or superior to
measures of financial performance prepared in accordance with GAAP
and should not be considered as an alternative to any other
performance measures derived in accordance with GAAP.
The Company believes that presenting these non-GAAP financial
measures provides useful supplemental information to investors
about the Company in understanding and evaluating its operating
results, enhancing the overall understanding of its past
performance and future prospects, and allowing for greater
transparency with respect to key financial metrics used by its
management in financial and operational-decision making. The
Company uses these non-GAAP measures to help assess its operating
performance and operating leverage in its business, analyze its
financial results, establish operational goals, develop operating
budgets, and make strategic decisions. The Company also believes
that the presentation of these non-GAAP financial measures provides
an additional tool for investors to use in comparing its core
business and results of operations over multiple periods with other
companies in its industry, many of which present similar non-GAAP
financial measures to investors, and to help analyze the Company’s
cash performance.
Other companies may calculate non-GAAP measures differently, or
may use other measures to calculate their financial performance,
and therefore any non-GAAP measures the Company uses may not be
directly comparable to similarly titled measures of other
companies. Further, there are a number of limitations related to
the use of non-GAAP measures and their nearest GAAP equivalents.
Accordingly, these non-GAAP financial measures should be considered
as supplemental in nature, should not be considered as the sole
measure of the Company’s performance, and are not intended to be
construed, and should not be considered, in isolation from, or as a
substitute for, the comparable or related financial information
calculated in accordance with GAAP.
These limitations of the non-GAAP financial measures presented
in this press release include the following:
- Adjusted EBITDA: (i) The exclusion of certain recurring,
non-cash charges, such as depreciation of property and equipment
and stock-based compensation expense. While these are non-cash
charges, the Company may need to replace the assets being
depreciated and amortized in the future and Adjusted EBITDA does
not reflect cash requirements for these replacements or new capital
expenditure requirements; and ii the exclusion of stock-based
compensation expense, which has been a significant recurring
expense and the Company expects will continue to constitute a
significant recurring expense for the foreseeable future, as equity
awards are expected to continue to be an important component of the
Company’s compensation strategy.
- Non-GAAP cost of revenue, non-GAAP selling, general, and
administrative expenses, and non-GAAP research and development
expenses: The exclusion of stock-based compensation expense, which
has been a significant recurring expense and the Company expects
will continue to constitute a significant recurring expense for the
foreseeable future, as equity awards are expected to continue to be
an important component of the Company’s compensation strategy.
In addition, non-GAAP selling, general, and administrative
expenses exclude non-recurring expense related to non-capitalized
transaction costs. While the Company expects this non-recurring
expense to cease, the Company expects new non-recurring expense
will be introduced following the Business Combination such as
change in fair value of the Company’s outstanding warrants which
the Company expects will constitute to be a significant expense
until all warrants are exercised and/or redeemed.
Because of these limitations, you should consider Adjusted
EBITDA, non-GAAP cost of revenue, non-GAAP selling, general, and
administrative expenses, and non-GAAP research and development
expenses alongside other financial performance measures, including
net loss and the Company’s other GAAP results. The information in
the tables below sets forth the non-GAAP financial measures along
with the most directly comparable GAAP financial measures.
A reconciliation of Adjusted EBITDA to net loss for the three
months ended June 30, 2021, March 31, 2021 and June 30, 2021 and
six months ended June 30, 2021 and 2020, respectively, are set
forth below:
(Unaudited and in thousands)
Three Months Ended
Six Months Ended
June 30, 2021
March 31, 2021
June 30, 2020
June 30, 2021
June 30, 2021
Net Loss
$
(30,557
)
$
(64,777
)
$
(10,003
)
$
(95,334
)
$
(26,429
)
Interest expense, net
179
147
34
326
74
Income tax expense
110
100
80
210
220
Depreciation and amortization
1,069
930
706
1,999
1,395
EBITDA
(29,199
)
(63,600
)
(9,183
)
(92,799
)
(24,740
)
Non-capitalized transaction costs*
79
961
30
1,040
30
Stock-based compensation
1,976
1,725
2,545
3,701
4,189
Forgiveness of PPP Loan
(2,860
)
—
—
(2,860
)
—
Equity method investment loss
604
(113
)
102
491
252
Change in fair value of debt
instruments
6,008
39,653
(312
)
45,661
2,222
Adjusted EBITDA
$
(23,392
)
$
(21,374
)
$
(6,818
)
$
(44,766
)
$
(18,047
)
A reconciliation of cost of revenue to non-GAAP cost of revenue
for the three months ended June 30, 2021, March 31, 2021, June 30,
2020 and six months ended June 30, 2021 and 2020, respectively, are
set forth below:
(Unaudited and in thousands)
Three Months Ended
Six Months Ended
June 30, 2021
March 31, 2021
June 30, 2020
June 30, 2021
June 30, 2020
Cost of revenue
$
4,549
$
3,734
$
6,522
$
8,283
$
13,085
Stock-based compensation
363
268
870
631
1,341
Non-GAAP Cost of revenue
$
4,186
$
3,466
$
5,652
$
7,652
$
11,744
A reconciliation of selling, general, and administrative
expenses to non-GAAP selling, general, and administrative expenses
for the three months ended June 30, 2021, March 31, 2021, June 30,
2020 and six months ended June 30, 2021 and 2020, respectively, are
set forth below:
(Unaudited and in thousands)
Three Months Ended
Six Months Ended
June 30, 2021
March 31, 2021
June 30, 2020
June 30, 2021
June 30, 2020
Selling, general and administrative
expenses
$
6,715
$
7,305
$
3,604
$
14,020
$
7,249
Stock-based compensation
442
409
345
851
767
Non-capitalized transaction costs*
79
961
30
1,040
30
Non-GAAP selling, general, administration
expenses
$
6,194
$
5,935
$
3,229
$
12,129
$
6,452
A reconciliation of research and development expenses to
non-GAAP research and development expenses for the three months
ended June 30, 2021, March 31, 2021, June 30, 2020 and six months
ended June 30, 2021 and 2020, respectively, are set forth
below:
(Unaudited and in thousands)
Three Months Ended
Six Months Ended
June 30, 2021
March 31, 2021
June 30, 2020
June 30, 2021
June 30, 2020
Research and development expenses
$
17,551
$
15,980
$
7,746
$
33,531
$
16,217
Stock-based compensation
1,171
1,048
1,330
2,219
2,081
Non-GAAP Research and development
expenses
$
16,380
$
14,932
$
6,416
$
31,312
$
14,136
∗ Non-capitalized transaction costs include non-recurring
expense related to the issuance of convertible loan notes and the
Business Combination.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210816005636/en/
For Rockley
Media John Christiansen, Camilla Scassellati Sforzolini Sard
Verbinnen & Co Rockley-SVC@sardverb.com
Investors Gwyn Lauber Rockley Photonics Holdings Limited
investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Apr 2023 to Apr 2024